新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 合约研究机构Medpace出售价或高达12亿美元

合约研究机构Medpace出售价或高达12亿美元

来源:生物谷 2013-11-19 19:47

2013年11月19日讯 /生物谷BIOON/ --目前合约研究机构Medpace正在待价而沽,而评论人士估计其最后价格或高达12亿美元。而Medpace公司目前的主人CCMP Capital Advisors借助目前CRO兼并热潮或将寻求现金支付。Medpace公司是CCMP2011年以近5亿美元收购的。在此之后,Medpace公司将业务范围扩大到欧洲市场并兼并了一些小型CRO。(生物谷Bioon.com)

详细英文报道:

CRO Medpace is on the block and could go for up to $1.2 billion, Reuters reports, as private equity owner CCMP Capital Advisors could be looking to cash out while the market for contract researchers remains bullish.

CCMP bought Medpace just two years ago, but the New York-headquartered outfit has already retained Jefferies to scout for buyers and is in the midst of early talks, Reuters sources say. That's a short gestation period in private equity terms, and CCMP is likely motivated by recent high-dollar consolidation in the CRO space and long-running market optimism for pharmaceutical outsourcing companies.

The private equity firm traded roughly $485 million for an 80% stake in Medpace back in 2011, Reuters notes, and if CCMP can secure a $1.2 billion cashout after just two years, the popularity of CROs as M&A targets is likely only to swell.

Over the past few years, sizable CROs have traded hands for weighty deals, including KKR's $1.3 billion grab for PRA, Carlyle and Hellman & Friedman's $3.9 billion acquisition of PPD, and a $1.1 billion leveraged buyout that took inVentiv Health off the public market.

Under CCMP's watch, Medpace has expanded its global footprint, opening offices across Europe and buying up smaller CROs to stretch out its offerings in medical device development.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库